Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Razuprotafib - Aerpio Pharmaceuticals

Drug Profile

Razuprotafib - Aerpio Pharmaceuticals

Alternative Names: AKB-9778

Latest Information Update: 17 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Aerpio Pharmaceuticals; Akebia Therapeutics; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; New York University; Quantum Leap Healthcare Collaborative
  • Class Amides; Antineoplastics; Antivirals; Carbamates; Eye disorder therapies; Small molecules; Sulfonic acids; Thiazoles; Thiophenes
  • Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adult respiratory distress syndrome; Diabetic macular oedema; Diabetic retinopathy; Ocular hypertension; Open-angle glaucoma; Retinal vein occlusion
  • No development reported Age-related macular degeneration; Breast cancer

Most Recent Events

  • 16 Sep 2020 Aerpio Pharmaceuticals completes enrollments in a phase-II clinical trial in Ocular hypertension and Open-angel glaucoma (Adjunctive treatment, Treatment-experienced) in USA (Ophthalmic, Liquid) (NCT04405245)
  • 17 Aug 2020 Aerpio Therapeutics in collaboration with Medical Technology Enterprise Consortium plans a phase II RESCUE trial for COVID-2019 infections in September 2020 (NCT04511650)
  • 04 Aug 2020 Aerpio Pharmaceuticals enters into an R&D agreement with Medical Technology Enterprise Consortium to evaluate razuprotafib for Adult respiratory distress syndrome
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top